InnoCan Pharma Statistics
Total Valuation
InnoCan Pharma has a market cap or net worth of CAD 108.97 million. The enterprise value is 104.37 million.
| Market Cap | 108.97M | 
| Enterprise Value | 104.37M | 
Important Dates
The next estimated earnings date is Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 | 
| Ex-Dividend Date | n/a | 
Share Statistics
InnoCan Pharma has 6.04 million shares outstanding. The number of shares has increased by 7.00% in one year.
| Current Share Class | 6.04M | 
| Shares Outstanding | 6.04M | 
| Shares Change (YoY) | +7.00% | 
| Shares Change (QoQ) | +0.66% | 
| Owned by Insiders (%) | 2.54% | 
| Owned by Institutions (%) | 0.13% | 
| Float | 5.12M | 
Valuation Ratios
| PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | 2.77 | 
| PB Ratio | 11.94 | 
| P/TBV Ratio | 19.00 | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
Enterprise Valuation
The stock's EV/EBITDA ratio is 217.40, with an EV/FCF ratio of -163.17.
| EV / Earnings | -48.56 | 
| EV / Sales | 2.65 | 
| EV / EBITDA | 217.40 | 
| EV / EBIT | 240.64 | 
| EV / FCF | -163.17 | 
Financial Position
The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.21.
| Current Ratio | 3.70 | 
| Quick Ratio | 2.70 | 
| Debt / Equity | 0.21 | 
| Debt / EBITDA | 3.97 | 
| Debt / FCF | -2.98 | 
| Interest Coverage | 26.50 | 
Financial Efficiency
Return on equity (ROE) is -4.84% and return on invested capital (ROIC) is 2.81%.
| Return on Equity (ROE) | -4.84% | 
| Return on Assets (ROA) | 2.01% | 
| Return on Invested Capital (ROIC) | 2.81% | 
| Return on Capital Employed (ROCE) | 3.93% | 
| Revenue Per Employee | n/a | 
| Profits Per Employee | n/a | 
| Employee Count | n/a | 
| Asset Turnover | 2.92 | 
| Inventory Turnover | 1.26 | 
Taxes
In the past 12 months, InnoCan Pharma has paid 1.28 million in taxes.
| Income Tax | 1.28M | 
| Effective Tax Rate | 148.97% | 
Stock Price Statistics
The stock price has increased by +26.22% in the last 52 weeks. The beta is 0.10, so InnoCan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 | 
| 52-Week Price Change | +26.22% | 
| 50-Day Moving Average | 14.94 | 
| 200-Day Moving Average | 13.13 | 
| Relative Strength Index (RSI) | 58.16 | 
| Average Volume (20 Days) | 1,650 | 
Short Selling Information
| Short Interest | n/a | 
| Short Previous Month | n/a | 
| Short % of Shares Out | n/a | 
| Short % of Float | n/a | 
| Short Ratio (days to cover) | n/a | 
Income Statement
In the last 12 months, InnoCan Pharma had revenue of CAD 39.32 million and -2.15 million in losses. Loss per share was -0.49.
| Revenue | 39.32M | 
| Gross Profit | 34.78M | 
| Operating Income | 433,707 | 
| Pretax Income | 857,868 | 
| Net Income | -2.15M | 
| EBITDA | 480,079 | 
| EBIT | 433,707 | 
| Loss Per Share | -0.49 | 
Balance Sheet
The company has 9.89 million in cash and 1.91 million in debt, giving a net cash position of 7.99 million or 1.32 per share.
| Cash & Cash Equivalents | 9.89M | 
| Total Debt | 1.91M | 
| Net Cash | 7.99M | 
| Net Cash Per Share | 1.32 | 
| Equity (Book Value) | 9.12M | 
| Book Value Per Share | 1.28 | 
| Working Capital | 10.89M | 
Cash Flow
In the last 12 months, operating cash flow was -617,829 and capital expenditures -21,822, giving a free cash flow of -639,651.
| Operating Cash Flow | -617,829 | 
| Capital Expenditures | -21,822 | 
| Free Cash Flow | -639,651 | 
| FCF Per Share | -0.11 | 
Margins
Gross margin is 88.45%, with operating and profit margins of 1.10% and -5.47%.
| Gross Margin | 88.45% | 
| Operating Margin | 1.10% | 
| Pretax Margin | 2.18% | 
| Profit Margin | -5.47% | 
| EBITDA Margin | 1.22% | 
| EBIT Margin | 1.10% | 
| FCF Margin | n/a | 
Dividends & Yields
InnoCan Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | -7.00% | 
| Shareholder Yield | -7.00% | 
| Earnings Yield | -1.97% | 
| FCF Yield | -0.59% | 
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
The last stock split was on September 5, 2025. It was a reverse split with a ratio of 0.015384615.
| Last Split Date | Sep 5, 2025 | 
| Split Type | Reverse | 
| Split Ratio | 0.015384615 | 
Scores
InnoCan Pharma has an Altman Z-Score of 4.9 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.9 | 
| Piotroski F-Score | 3 |